Genzyme Will Appeal Lemtrada “Complete Response” After FDA Seeks More Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.
You may also be interested in...
Genzyme Nabs Elusive Lemtrada Approval, But As Third-Line MS Therapy
FDA says therapy for relapsing multiple sclerosis should be reserved for patients who fail two or more other MS treatments; REMS includes four-year follow up.
On The Offense: Sanofi Suits Up For A Game Change
Having exited its patent cliff and advanced several drugs into late-stage development, Sanofi is moving into a new commercial-centric phase. Its future looks bright, but success is not guaranteed.
NICE's Unrestricted MS Indication For Lemtrada Could Boost It Ahead Of Rivals
Though not totally convinced about long-term effectiveness and patient adherence, NICE's decision not to restrict Lemtrada's indication could place it ahead of Gilenya and Tysabri for relapsing-remitting multiple sclerosis.